6 stories mentioning QURE
Every FINWIRES story that references QURE, newest first.
Walid Abi-Saab, Chief Medical Officer, on May 08, 2026, sold 45,000 shares in Uniqure (QURE) for $1,127,500. Following the Form 4 filing with the SEC, Abi-Saab has control over a total of 169,669 ordinary shares of the company, with 169,669 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1590560/000090445426000260/xslF345X05/edgar.xml
UniQure (QURE) shares fell 1.8% in early Tuesday trading after the company posted a wider Q1 loss.The company reported a Q1 loss Tuesday of $0.85 per diluted share, widening from a loss of $0.82 a year earlier.Analysts surveyed by FactSet expected a loss of $0.85.Revenue for the quarter ended March 31 was $3.6 million, up from $1.6 million a year earlier.Analysts polled by FactSet expected $5.2 million.Price: $20.30, Change: $-0.38, Percent Change: -1.84%
Health care stocks rose late Thursday afternoon with the NYSE Health Care Index climbing 2.6% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 2.3%.The iShares Biotechnology ETF (IBB) advanced 1.9%.In corporate news, UniQure (QURE) shares jumped past 16% after the company said it plans to submit a UK marketing authorization application in Q3 for AMT-130 to treat Huntington's disease.Axsome Therapeutics (AXSM) shares surged 12% after it said the US Food and Drug Administration approved Auvelity to treat agitation associated with Alzheimer's disease dementia.Eli Lilly (LLY) raised its full-year outlook and reported Q1 results above market estimates as sales of Mounjaro more than doubled. Lilly shares jumped past 10%.The US Food and Drug Administration is proposing to exclude tirzepatide, semaglutide and liraglutide from the 503B bulks list, finding no clinical need for outsourcing facilities to compound the drugs from bulk substances. Eli Lilly makes tirzepatide, marketed as Mounjaro for type 2 diabetes and Zepbound for chronic weight management. Novo Nordisk (NVO) makes semaglutide, marketed as Ozempic for type 2 diabetes and Wegovy for chronic weight management, and liraglutide, under the brand name Victoza for type 2 diabetes and Saxenda for chronic weight management. Novo shares rose past 5%.
Health care stocks rose late Thursday afternoon with the NYSE Health Care Index climbing 2.6% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 2.3%.The iShares Biotechnology ETF (IBB) advanced 1.9%.In corporate news, UniQure (QURE) shares jumped past 16% after the company said it plans to submit a UK marketing authorization application in Q3 for AMT-130 to treat Huntington's disease.
(Updates with the latest stock move in the headline and in the first paragraph.)UniQure (QURE) shares were up over 18% in Thursday trading after the company said it plans to submit a UK marketing authorization application in Q3 for AMT-130 for the treatment of Huntington's disease.The plan came after a pre-submission meeting with the UK's Medicines and Healthcare products Regulatory Agency, it said.The company said it has also been granted a Type B meeting with the US Food and Drug Administration in Q2, and expects to discuss key elements of a potential phase III trial design.The company said it is pursuing additional regulatory pathways in international markets for the potential registration of AMT-130 and expects to provide further updates in H2.Price: $19.82, Change: $+3.09, Percent Change: +18.47%
UniQure (QURE) said Thursday it plans to submit a UK marketing authorization application in Q3 for AMT-130 for the treatment of Huntington's disease.The decision to submit was made after a pre-submission meeting with the UK's Medicines and Healthcare products Regulatory Agency, the company said.The company said it has also been granted a Type B meeting with the US Food and Drug Administration in Q2, and expects to discuss key elements of a potential phase III trial design and to receive feedback on analysis plan in Q3.The company is actively pursuing additional regulatory pathways in international markets for the potential registration of AMT-130 and expects to provide further updates in H2, it said.Price: $19.02, Change: $+2.29, Percent Change: +13.66%